(Q35684825)

9 August 2017

1 reference

title

The effect of fibrates and other lipid-lowering drugs on plasma homocysteine levels (English)

1 reference

9 August 2017

3

Claus Luley

1 reference

9 August 2017

Jutta Dierkes

1

1 reference

PubMed ID

15006716

9 August 2017

Sabine Westphal

series ordinal

2

1 reference

PubMed ID

15006716

9 August 2017

language of work or name

English

0 references

publication date

1 March 2004

1 reference

Expert Opinion on Drug Safety

9 August 2017

1 reference

9 August 2017

3

1 reference

9 August 2017

2

1 reference

9 August 2017

101-111

1 reference

A strategy to reduce cardiovascular disease by more than 80%

9 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.2.101

Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen Male Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.2.101

The role of fibric acids in atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.2.101

The evolving role of statins in the management of atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.2.101

Influence of nicotinic acid on serum cholesterol in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.2.101

Homocyst(e)ine and cardiovascular disease: a critical review of the epidemiologic evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.2.101

Decreased rate of coronary restenosis after lowering of plasma homocysteine levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.2.101

Homocysteine and atherothrombosis--mechanisms for injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.2.101

Hyperhomocyst(e)inemia is associated with impaired endothelium-dependent vasodilation in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.2.101

Impairment of endothelial functions by acute hyperhomocysteinemia and reversal by antioxidant vitamins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.2.101

MTHFR 677C-->T polymorphism and risk of coronary heart disease: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.2.101

Biological and environmental determinants of plasma homocysteine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.2.101

The increase of plasma homocysteine concentrations with age is partly due to the deterioration of renal function as determined by plasma cystatin C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.2.101

Drugs affecting homocysteine metabolism: impact on cardiovascular risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.2.101

Fenofibrate raises plasma homocysteine levels in the fasted and fed states

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.2.101

Effects of fenofibrate and gemfibrozil on plasma homocysteine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.2.101

Effect of folic acid on fenofibrate-induced elevation of homocysteine and cysteine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.2.101

Vitamin supplementation can markedly reduce the homocysteine elevation induced by fenofibrate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.2.101

Fibrate-induced increase in blood urea and creatinine: is gemfibrozil the only innocuous agent?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.2.101

Pharmacology of cyclooxygenase-2 inhibition in the kidney

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.2.101

Fenofibrate induces a selective increase of protein-bound homocysteine in rodents: a PPARalpha-mediated effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.2.101

The effect of creatine and resistance training on plasma homocysteine concentration in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.2.101

Investigation of relationship between reduced, oxidized, and protein-bound homocysteine and vascular endothelial function in healthy human subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.2.101

High-dose simvastin (80 mg/day) decreases plasma concentrations of total homocyst(e)ine in patients with hypercholesteromia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.2.101

Pathophysiology and clinical importance of hyperhomocysteinemia: clinical intervention studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.2.101

Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.2.101

Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.2.101

Pravastatin treatment-associated reduction in plasma homocysteine in heart-transplanted patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.2.101

Fluvastatin therapy improves microcirculation in patients with hyperlipidaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.2.101

Comparative effects of atorvastatin, simvastatin, and fenofibrate on serum homocysteine levels in patients with primary hyperlipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.2.101

Effects of atorvastatin on oxidized low-density lipoprotein, low-density lipoprotein subfraction distribution, and remnant lipoprotein in patients with mixed hyperlipoproteinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.2.101

Folate supplementation prevents plasma homocysteine increase after fenofibrate therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.2.101

Both fenofibrate and atorvastatin improve vascular reactivity in combined hyperlipidaemia (fenofibrate versus atorvastatin trial--FAT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.2.101

21 January 2018

Identifiers

DOI

10.1517/14740338.3.2.101

1 reference

9 August 2017

1 reference

PubMed ID

15006716